Abstract:Background Activation of anticancer T cell immunity by checkpoint inhibition has become a key tool in the clinical management of cancer, but efficacy is limited in part by the suppressive activity of myeloid cells. Reprogramming myeloid cells from a suppressive into an immune-enhancing state is a goal of significant translational interest. Using preclinical and clinical studies, we investigated the potential of JAK inhibitors to enhance the efficacy of checkpoint inhibitors in a myeloid-dependent manner. Methods The combination therapy of systemic treatment with the JAK inhibitor ruxolitinib with anti-PD1 + anti-CTLA4 was evaluated for efficacy and biomarkers compared to checkpoint inhibitors (ICI) alone in four murine immunocompetent models of cancer. Tumor-infiltrating, blood and lymphoid organ immune cells were phenotyped using single-cell transcriptomics, functional assays and flow cytometry. The combination therapy was clinically tested in an investigator-initiated Phase I/II clinical trial of ruxolitinib with nivolumab in relapsed or refractory Hodgkin lymphoma (NCT03681561). Patients who previously failed to respond to ICI received ruxolitinib for 1 week then nivolumab every 4 weeks concurrent with ruxolitinib. Hematologic, transcriptomic and flow cytometric analyses were performed on peripheral blood collected at baseline and after ruxolitinib treatment. Results The ruxolitinib + ICI combination was superior to ICI in 3/4 of the tumor models examined in controlling tumor growth. Compared to ICI alone, tumor sizes were reduced by >50% in the MC38 (mean volume 123.1 vs 283.2 mm3, n=9 per group, p=0.0094), LLC1 and A20 models (survival hazard ratio 0.47, n=30 per group, p=0.025). Remarkably, we observed a broad shift of tumor monocytes and granulocytes from a suppressive into an immunostimulatory state characterized by the expression of MHC-II and the ability to stimulate T cell proliferation. Depleting monocytic or granulocytic cells abrogated the beneficial effect of ruxolitinib. Hodgkin lymphoma patients in the ruxolitinib with nivolumab trial exhibited a disease control rate of 63% (12/19) including 5 complete responses. Ruxolitinib treatment in these patients did not impair T cell numbers or cytokine production but significantly reduced the neutrophil-to-lymphocyte ratio (NLR, mean difference -0.82, n=14, p=0.0023) and the percentage of LOX1+ granulocytic suppressor cells in peripheral blood (mean 0.27 of baseline, p=0.0009). The reduction in NLR was significantly greater in complete responders than in progressive disease patients (mean -2.6 vs -0.58, respectively, p=0.023). Conclusions The combination of ruxolitinib with ICI was effective in preclinical models and in a Phase I/II Hodgkin lymphoma clinical trial, identifying JAK inhibition with ICI as a promising myeloid-modulating immunotherapy. Trial Registration The clinical trial identifier number is NCT03681561. Ethics Approval This work was approved by the Institutional Review Boards of the University of Minnesota (STUDY00001341) and The Scripps Research Institute (IRB-19–7408, IRB-21–7803).

The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

Immune modulation with RANKL blockade through denosumab treatment in patients with cancer

Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases

Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review

Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study

Abstract B005: Denosumab Enhances Cytotoxic T Cell Infiltration by supressing SPP1 Expression in Giant Cell Tumour of Bone

Real-world Data of Efficacy and Safety of Denosumab on Patients with Breast Cancer with Bone Metastasis: Results from Chinese Clinical Experience.

Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study

Efficacy and Safety of Denosumab from A Phase Iii, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.

High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy

Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials

847 Optimal Dose Selection of ADG126 (a Masked Anti-Ctla-4 SAFEbody®) with Significantly Widened Therapeutic Index Compared to Ipilimumab in Combination with Anti-Pd-1 Antibodies Informed by QSP Modeling

Pembrolizumab Monotherapy or Combination Therapy for Bone Metastases in Advanced Non-Small Cell Lung Cancer: a Real-World Retrospective Study.

RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials